iCleanse Announces Collaboration with CIT to Offer Low-Interest Financing on All iCleanse Disinfection Products to Kill COVID

iCleanse www.icleanse.com, the leader in UV-C personal device disinfection, announced today that it has joined forces with CIT, a top 50 national bank, to provide low-interest financing on all iCleanse disinfection products to keep customers and staff safe from infectious pathogens.

This alliance allows iCleanse to better serve its current and future customer base, who may have limited cash flow due to the year-long pandemic, making UV-C disinfection more attainable for small and large businesses alike and keeping businesses open. iCleanse products kill 99.9% of infectious pathogens, such as COVID-19, the common cold, and influenza in as little as 15 seconds.

iCleanse’s Mission: Help Businesses Remain Safe and Open

iCleanse is the leader and only patented solution in chemical-free UV-C disinfection for mobile devices. Providing quick and effective disinfection for all types of business to help them remain safe and open is the main objective in iCleanse’s mission. Applying for financing through CIT is quick and easy, and customers can receive a decision on financing often in less than three minutes.

“Being able to offer our customers an easy financial solution to purchase our products is a no-brainer,” said Chris Allen, CEO of iCleanse. “Ensuring easy and effective disinfection of the items we use daily is one way to reduce the spread of the COVID-19 pandemic.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”